Neumora Therapeutics is trading at $1.51 (-5.59%) after investors absorbed its August 14, 2026 earnings release and leadership transition.
- Although its $43.1 million quarterly loss narrowed, cash is projected to fund operations into the third quarter of 2027.
- The company remains pre-revenue and is restructuring around its obesity and neuroscience pipeline.
- Joshua Pinto became CEO, while Paul Berns moved to executive chair.